Payment overview · 2025
General Payments
$359.52
13 reported records · 5 companies
Healthcare provider profile · identity verified
Douglas Alorgbey, M.D
Allopathic & Osteopathic Physicians|Family Medicine · EL PASO, TX · NPI 1871938647
Verified facts
What the public records show
CMS Open Payments records show Douglas Alorgbey, M.D received $359.52 in general payments during 2025 across 13 reported records.
AngioDynamics, Inc. accounted for 36.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $129.27 | 36.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $107.80 | 30.0% | 6 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $69.68 | 19.4% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $38.61 | 10.7% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.16 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $359.52 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AURYON LASER SYSTEM 100-120 VAC Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $129.27 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $107.80 | 6 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $69.68 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $38.61 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
25 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
106 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 713 | 237 |
| Levothyroxine Sodium | Levothyroxine Sodium | 468 | 106 |
| Lisinopril | Lisinopril | 435 | 125 |
| Metformin Hcl | Metformin Hcl | 428 | 129 |
| Eliquis | Apixaban | 293 | 67 |
| Losartan Potassium | Losartan Potassium | 284 | 100 |
| Amlodipine Besylate | Amlodipine Besylate | 279 | 111 |
| Pantoprazole Sodium | Pantoprazole Sodium | 256 | 114 |
| Furosemide | Furosemide | 253 | 83 |
| Gabapentin | Gabapentin | 244 | 91 |
| Memantine Hcl | Memantine Hcl | 208 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 208 | 82 |
| Metoprolol Succinate | Metoprolol Succinate | 164 | 60 |
| Ibuprofen | Ibuprofen | 160 | 88 |
| Prednisone | Prednisone | 148 | 106 |
| Tramadol Hcl | Tramadol Hcl | 148 | 89 |
| Omeprazole | Omeprazole | 147 | 53 |
| Sertraline Hcl | Sertraline Hcl | 147 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 142 | 56 |
| Azithromycin | Azithromycin | 139 | 101 |
| Trazodone Hcl | Trazodone Hcl | 137 | 52 |
| Fluticasone Propionate | Fluticasone Propionate | 135 | 97 |
| Glipizide | Glipizide | 135 | 51 |
| Mirtazapine | Mirtazapine | 135 | 31 |
| Donepezil Hcl | Donepezil Hcl | 132 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 130 | 59 |
| Clopidogrel | Clopidogrel Bisulfate | 129 | 50 |
| Januvia | Sitagliptin Phosphate | 124 | 25 |
| Finasteride | Finasteride | 120 | 31 |
| Zolpidem Tartrate | Zolpidem Tartrate | 114 | 31 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 113 | 29 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 109 | 80 |
| Alendronate Sodium | Alendronate Sodium | 107 | 46 |
| Carvedilol | Carvedilol | 107 | 40 |
| Ozempic | Semaglutide | 106 | 27 |
| Levofloxacin | Levofloxacin | 103 | 90 |
| Alprazolam | Alprazolam | 97 | 40 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 96 | 74 |
| Buspirone Hcl | Buspirone Hcl | 93 | 32 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 93 | 31 |
| Montelukast Sodium | Montelukast Sodium | 88 | 39 |
| Hydralazine Hcl | Hydralazine Hcl | 87 | 37 |
| Dicyclomine Hcl | Dicyclomine Hcl | 85 | 61 |
| Allopurinol | Allopurinol | 84 | 23 |
| Meloxicam | Meloxicam | 83 | 22 |
| Simvastatin | Simvastatin | 82 | 23 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 80 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 79 | 35 |
| Spironolactone | Spironolactone | 74 | 24 |
| Nifedipine Er | Nifedipine | 73 | 24 |
| Famotidine | Famotidine | 71 | 32 |
| Potassium Chloride | Potassium Chloride | 71 | 23 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 71 | 52 |
| Escitalopram Oxalate | Escitalopram Oxalate | 64 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 64 | 46 |
| Naproxen | Naproxen | 63 | 39 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 60 | 44 |
| Fenofibrate | Fenofibrate,micronized | 60 | 30 |
| Pregabalin | Pregabalin | 56 | 25 |
| Cephalexin | Cephalexin | 54 | 44 |
| Lorazepam | Lorazepam | 51 | 12 |
| Fenofibrate | Fenofibrate | 49 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 49 | 43 |
| Meclizine Hcl | Meclizine Hcl | 48 | 35 |
| Clonazepam | Clonazepam | 46 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 46 | 29 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 46 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 46 | 25 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 45 | 29 |
| Xarelto | Rivaroxaban | 45 | 12 |
| Brilinta | Ticagrelor | 43 | suppressed |
| Entresto | Sacubitril/Valsartan | 43 | suppressed |
| Levetiracetam | Levetiracetam | 43 | 11 |
| Mounjaro | Tirzepatide | 41 | 13 |
| Trulicity | Dulaglutide | 41 | 12 |
| Divalproex Sodium | Divalproex Sodium | 40 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 40 | 18 |
| Temazepam | Temazepam | 40 | 11 |
| Baclofen | Baclofen | 39 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 36 | 11 |
| Lactulose | Lactulose | 35 | 24 |
| Ezetimibe | Ezetimibe | 34 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | 14 |
| Amoxicillin | Amoxicillin | 33 | 23 |
| Celecoxib | Celecoxib | 33 | 18 |
| Jardiance | Empagliflozin | 30 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 29 | 11 |
| Glipizide Er | Glipizide | 28 | suppressed |
| Metronidazole | Metronidazole | 28 | 23 |
| Risperidone | Risperidone | 28 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 27 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 27 | 16 |
| Ondansetron Odt | Ondansetron | 27 | 21 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 26 | 14 |
| Latanoprost | Latanoprost | 26 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | 11 |
| Hydrocortisone | Hydrocortisone | 25 | 14 |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 25 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 25 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 24 | 17 |
| Atenolol | Atenolol | 24 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 24 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 23 | 15 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 23 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 22 | 13 |
| Methocarbamol | Methocarbamol | 22 | 15 |
| Primidone | Primidone | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 21 | 13 |
| Diltiazem Hcl | Diltiazem Hcl | 20 | suppressed |
| Olanzapine | Olanzapine | 20 | suppressed |
| Fluconazole | Fluconazole | 19 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | 14 |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 18 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Ofloxacin | Ofloxacin | 17 | 13 |
| Oxcarbazepine | Oxcarbazepine | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Dexamethasone | Dexamethasone | 16 | 14 |
| Linzess | Linaclotide | 16 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 16 | 15 |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | 11 |
| Sucralfate | Sucralfate | 16 | 15 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 14 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Nystatin | Nystatin | 13 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Admelog Solostar | Insulin Lispro | 12 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Insulin Lispro Junior Kwikpen | Insulin Lispro | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Rifampin | Rifampin | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $359.52 · 13 records | AngioDynamics, Inc. | AIRSUPRA, AURYON LASER SYSTEM 100-120 VAC, FREESTYLE LIBRE 3, Kerendia | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error